<DOC>
	<DOC>NCT02286362</DOC>
	<brief_summary>This non-interventional prospective study will assess the safety of Herceptin SC (subcutaneous administration) as used in routine clinical practice. Patients with HER2-positive early breast cancer, naive and non-naive of HER2+ treatment who are to be treated in the neoadjuvant and adjuvant setting and scheduled to initiate a treatment with Herceptin SC in routine clinical practice use are eligible to participate. The total study duration is anticipated to be 38 months.</brief_summary>
	<brief_title>An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Aged &gt;/= 18 years Patients with HER2positive early breast cancer who according to national guidelines are eligible for neoadjuvant or adjuvant HER2+ treatment Patients for whom the investigator has decided to start a treatment with Herceptin SC Trastuzumab treatment naive or nonnaive (previously intravenous treatment) Informed consent Patients previously treated with Herceptin SC treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>